Targeted pill aims to halt recurrent uterine cancer
NCT ID NCT02491099
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug afatinib in 50 women with a rare, aggressive uterine cancer (HER2-positive uterine serous carcinoma) that has persisted or returned. Afatinib is a daily pill that blocks a protein driving cancer growth. The main goal is to see if it can keep the cancer from worsening for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Afatinib (a targeted cancer pill)
- What this could lead to
- If successful, this could offer a new treatment option to slow or shrink HER2-positive uterine serous carcinoma that has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early-phase trial (50 participants) with no control group. The drug may not improve outcomes and can cause side effects like diarrhea, rash, or mouth sores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2/NEU+ UTERINE SEROUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
COMPLETEDBoston, Massachusetts, 02114, United States
-
University of Arizona Cancer Center
COMPLETEDTucson, Arizona, 85724, United States
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States